The company historically manufactured electrical conductors and cables for power transmission and distribution; however, it has recently pivoted toward trading agricultural products and diversified its charter to include real estate, IT, and jewelry.
The company lacks any identifiable competitive advantage, as evidenced by its negative net margins and low returns on capital. The recent shift from manufacturing to high-volume, low-margin agricultural trading suggests a lack of specialized pricing power or brand strength.
Management has shifted capital away from its core manufacturing assets toward unsecured loans to third parties and speculative trading in unrelated sectors. The massive issuance of warrants at low prices and the withdrawal of a rights issue indicate a lack of disciplined capital planning.
The company collapsed as the massive unsecured loans to third parties were never recovered, revealing them as a total loss of shareholder capital. The shift into low-margin agricultural trading proved to be a desperate attempt to inflate revenue without profit, eventually leading to insolvency when the auditor's inability to verify transactions turned into a formal finding of fraud. With the board having fled and the trade name legally stripped away, the remaining shell was delisted after failing to produce even basic accounting records.
RichFakir rates Auri Grow India Ltd's business quality as poor — 8/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Auri Grow India Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Auri Grow India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Auri Grow India Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →